Healthcare / Diagnostics & ResearchBSE
$14.53
-0.15 (-1.02%)
FCF base 3Y
n/d
n/d CAGR · yield n/d
FCF base 5Y
n/d
n/d base · n/d expected
Precio de entrada
n/d
MOS 33% · confianza 21%
FCF escenarios
weak_data · normalized FCF $-1.3M · quality 60.3/100
Ranking barato/determinista: CAGR esperado 5Y + downside bear + calidad del modelo + balance + capital allocation + data gate. No entra en buy-candidate si la data es débil o el CAGR 5Y no compensa.
SA Score
12/100
F
Piotroski
1/9
balance/quality
Valuation
50/100
+0.0% upside
5Y CAGR
+0.0%
50/100
Data QA
16/100
SEC 0%
Sin guardar todavía.
Market Cap
$331M
P/E
N/A
•EV/EBITDA
N/A
•ROE
-2.4%
↓Gross Margin
N/A
•Debt/Equity
0.20
↓TradingView lightweight chart
Absolute Values (Left Axis)
Ratios / Percentages (Right Axis)
Financial statement dashboard
2022–2025 · 3 años de histórico normalizado
Revenue CAGR
—
FCF CAGR
—
FCF margin
—
FCF / Net income
0.79x
Latest source
Provider fallback
Margin decomposition
Último año: revenue — · net income $-2.8M · FCF $-2.3M
Gross margin
Operating margin
Net margin
FCF margin
| Metric | TTM | 2025 | 2024 | 2023 | 2022 |
|---|---|---|---|---|---|
| Income Statement | |||||
| Revenue | — | — | — | $216440.00 | $224540.00 |
| Net Income | $-2.8M | $-2.8M | $-2.6M | $-7.1M | $14.9M |
| EBITDA | $-2.6M | $-2.6M | $-2.5M | $-2.5M | $-4.0M |
| EPS | -0.19 | -0.19 | -0.18 | -0.48 | 1.01 |
| Gross Margin | — | — | — | 5.7% | -571.6% |
| Operating Margin | — | — | — | -1169.6% | -1799.5% |
| Net Margin | — | — | — | -3260.5% | 6623.8% |
| Balance Sheet | |||||
| Debt/Equity | 0.20 | 0.20 | 0.18 | 0.17 | 0.21 |
| Cash Flow | |||||
| Free Cash Flow | $-2.3M | $-2.3M | $-1.3M | $6.6M | $-19.0M |
| Returns | |||||
| ROE | -2.4% | -2.4% | -2.1% | -5.6% | 11.2% |
| Valuation | |||||
| P/E | — | — | — | — | 28.22 |
| P/B | 1.80 | 1.80 | 2.15 | 2.69 | 3.19 |
| Growth & Yield | |||||
| Revenue Growth | — | — | — | -3.6% | — |
| EPS Growth | -5.6% | -5.6% | 62.5% | -147.5% | — |
Revenue, Net Income & Free Cash Flow ($B)
Margins (%)
Returns (%)
Leverage & Liquidity
Qué te dice: cuánto EPS CAGR está descontando el precio si sales al múltiplo terminal indicado. Si el growth observado queda por debajo, el mercado está pidiendo una ejecución muy fina.
Total return
-32.1%
Start / end P/E
n/dx → n/dx
EPS bridge
-0.18 → -0.19
Residual
-32.1%
EPS/multiple decomposition requires positive EPS at both endpoints; residual absorbs price move not explained by dividends.
Simple additive decomposition: total return = EPS growth contribution + P/E multiple contribution + dividend contribution + explicit residual. The residual captures cross-terms, buybacks/share-count effects, FX, special dividends, data noise and methodology mismatch so the bridge always reconciles.